Newsfeeds - Spark Newswire

3 minute read

The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration

Today, 8:09 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)

AGEN

5 minute read

The Daily Biotech Pulse: Early Approval For Ascendis’ Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO

By Shanthi Rexaline

Today, 8:09 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25)

ABBV

9 minute read

Stocks That Hit 52-Week Highs On Wednesday

By Benzinga Insights

Today, 8:09 PM

Before 10 a.m. ET on Wednesday, 124 companies hit new 52-week highs.

1 minute read

A Look Into Catalent’s Price Over Earnings

By Benzinga Insights

Today, 8:09 PM

CTLT

2 minute read

Catalent’s Debt Overview

By Benzinga Insights

Today, 8:09 PM

Shares of Catalent (NYSE:CTLT) rose by 23.76% in the past three months. Before having a look at the importance of debt, let us look at how much debt Catalent has.

CTLT

1 minute read

EMA Approves Additional Sites To Boost Output Capacity For mRNA-Based COVID-19 Vaccines

By Vandana Singh

Today, 8:09 PM

European Medical Agency (EMA) has approved additional manufacturing sites for mRNA-based coronavirus vaccines developed by Pfizer Inc (NYSE:PFE) – BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA)…

BNTX

2 minute read

Unusual Options Activity Insight: Catalent

By Benzinga Insights

Today, 8:09 PM

On Monday, shares of Catalent (NYSE:CTLT) saw unusual options activity. After the option alert, the stock price moved up to $121.14.

CTLT

1 minute read

News

Catalent Will Supply Edenbridge Pharma With Patient-Focused Fast-Dissolve Zydis Formulation Of Glycopyrrolate

By Benzinga Newsdesk

Today, 8:09 PM

-Reuters

CTLT

1 minute read

Catalent Plans $100M Expansion Of Biologics Capabilities At Italian Vaccine Plant

By Vandana Singh

Today, 8:09 PM

Catalent Inc (NYSE: CTLT) will begin the first phase of a planned $100 million expansion at its facility in Anagni, Italy,

AZN

2 minute read

News

Catalent Announced Plans for Multi-Phase, $100M Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe

By Charles Gross

Today, 8:09 PM

Catalent (NYSE: CTLT) today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.

CTLT